Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin

Pharmacotherapy

Volumn 30, Issue 1, 2010, Pages 35-42

  Goldberg, Michael R ^a   Wong, Shekman L ^a   Shaw, Jeng Pyng ^a   Kitt, Michael M ^a   Barriere, Steven L ^a  

^a THERAVANCE INC   (United States)

Author keywords

Hepatic impairment; Pharmacokinetics; Telavancin

Indexed keywords

DRUG METABOLITE; TELAVANCIN; THRX 651540; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISPOSITION; DRUG FATALITY; DRUG HYDROXYLATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY MONITORING; EQUILIBRIUM DIALYSIS; FATIGUE; FEMALE; HEADACHE; HUMAN; LABORATORY TEST; LIQUID CHROMATOGRAPHY; LIVER DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PILOT STUDY; SIDE EFFECT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VITAL SIGN; VOMITING;

ADOLESCENT; ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEPATIC INSUFFICIENCY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 75149167999     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.1.35     Document Type: Article

References (24)

1. Leadbetter MR, Adams SM, Bazzini B, et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo) 2004;57:326-36.
2. Pace JL, Judice JK. Telavancin (Theravance). Curr Opin Investig Drugs 2005;6:216-25.
3. Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin Investig Drugs 2007;16:347-57.
4. Nannini EC, Stryjewski ME. A new lipoglycopeptide: telavancin. Expert Opin Pharmacother 2008;9:2197-207.
5. Leonard SN, Rybak MJ. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacotherapy 2008;28:458-68.
6. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:1127-34.
7. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother 2004;53:797-803.
8. Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:3602-4.
9. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic grampositive species and Corynebacterium spp. Antimicrob Agents Chemother 2004;48:2149-52.
10. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58:338-43.
11. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004;48:3043-50.
12. Reyes N, Skinner R, Kaniga K, et al. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:4344-6.
13. Madrigal AG, Basuino L, Chambers HF. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycinintermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:3163-5.
14. Stucki A, Gerber P, Acosta F, Cottagnoud M, Cottagnoud P. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 2006;50:770-3.
15. Reyes N, Skinner R, Benton BM, et al. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58:462-5.
16. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. In vitro activity of telavancin against recent gram-positive clinical isolates: results of the 2004-05 prospective European surveillance initiative. J Antimicrob Chemother 2008;62:116-21.
17. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. Comparative surveillance study of telavancin activity against recent gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52:2383-8.
18. Yin LY, Calhoun JH, Thomas TS, Wirtz ED. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. J Antimicrob Chemother 2009;63:357-60.
19. Hegde SS, Reyes N, Skinner R, Difuntorum S. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. J Antimicrob Chemother 2008;61:169-72.
20. Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 2008;52:2647-52.
21. Hegde SS, Difuntorum S, Skinner R, Trumbull J, Krause KM. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. J Antimicrob Chemother 2009;63:763-6.
22. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49:195-201.
23. Wong S, Barriere S, Kitt M, Goldberg M. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 2008;62:780-3.
24. Duchin K, Shaw J, Spencer E, Seroogy J, Barriere S, Wilbraham D. Single dose pharmacokinetics (PK) of telavancin (TLV) in subjects with renal dysfunction [abstract P1028]. Clin